Carlos Bermúdez

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Thomas E. Witzig, Kensei Tobinai, Luigi Rigacci et al. · Annals of Oncology · 2017 · 66 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

Thomas E. Witzig, Kensei Tobinai, Luigi Rigacci et al. · Journal of Clinical Oncology · 2016 · 18 citations

Pharmacy, Oncology, Pharmacotherapy +17

Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial

I V Poddubnaya, Kamil Kaplanov, Les M. Lukavetskyy et al. · Hematological Oncology · 2019 · 15 citations

Pharmacy, Immunology, Pharmacokinetics +15

A Comparison of Recombination Operators for Capacitate Vehicle Routing Problem

Carlos Bermúdez, Patricia Graglia, Natalia Stark et al. · INTELIGENCIA ARTIFICIAL · 2010 · 10 citations · Full text

Natural Sciences, Transportation Planning, Optimization +16